Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,556.37
(
-0.37%
)
US TECH 100
23,597.60
(
1.02%
)
Dow Jones
46,124.06
(
-0.18%
)
Brent Oil
96.91
(
0.42%
)
Bitcoin
71,124.33
(
0.86%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 116047

Friday, 06/22/2018 11:04:41 AM

Friday, June 22, 2018 11:04:41 AM

Post# of 257275
Alexo Therapeutics—>ANX Oncology—(private CD47 company):

https://www.businesswire.com/news/home/20180622005026/en

ALX Oncology is developing ALX148, a high affinity CD47 blocker currently in clinical development (https://www.clinicaltrials.gov/ct2/show/NCT03013218 ).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up